Application | Comment | Organism |
---|---|---|
medicine | genetic variation of inosine triphosphatase causing an accumulation of inosine triphosphate protects patients against ribavirin-induced anemia during treatment for chronic hepatitis C infection. ITP can be used for ATP biosynthesis via adenylosuccinate synthase in place of guanosine triphosphate. With ribavirin challenge, erythrocyte ATP reduction is more severe in the wild-type inosine triphosphatase ITPA genotype than in the hemolysis protective ITPA genotype. The alleviation of ATP reduction by the hemolysis protective ITPA genotype is canceled by the adenylosuccinate synthase inhibitor 6-mercaptoethanol | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
erythrocyte | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ITP + IMP + L-Asp | - |
Homo sapiens | IDP + phosphate + adenylosuccinate | ITP can be used for ATP biosynthesis via adenylosuccinate synthase in place of guanosine triphosphate | ? |
General Information | Comment | Organism |
---|---|---|
physiological function | genetic variation of inosine triphosphatase causing an accumulation of inosine triphosphate protects patients against ribavirin-induced anemia during treatment for chronic hepatitis C infection. ITP can be used for ATP biosynthesis via adenylosuccinate synthase in place of guanosine triphosphate. With ribavirin challenge, erythrocyte ATP reduction is more severe in the wild-type inosine triphosphatase ITPA genotype than in the hemolysis protective ITPA genotype. The alleviation of ATP reduction by the hemolysis protective ITPA genotype is canceled by the adenylosuccinate synthase inhibitor 6-mercaptoethanol | Homo sapiens |